Physician profile
Sergey Gorbachev
NPI 1831220417
$4,839.23
in general payments reported to CMS, 2019-2025
21 companies · $732 in 2025
The $732 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $573 · 2021: $304 · 2022: $249 · 2023: $563 · 2024: $1,276 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,182.23 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $726.23 | 2019-2024 | Arexvy |
| Janssen Pharmaceuticals, INC | $272.36 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $248.81 | 2022-2023 | Quviviq |
| Abbvie INC. | $243.05 | 2024 | |
| Allergan, INC. | $225.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.51 | 2019-2024 | Spevigo |
| Alkermes, INC. | $217.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $195.58 | 2019 | |
| Edwards Lifesciences Corporation | $176.23 | 2023-2024 | |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $124.96 | 2022 | |
| Akebia Therapeutics INC | $121.84 | 2025 | Vafseo |
| Boston Scientific Corporation | $113.97 | 2020 | |
| Vanda Pharmaceuticals INC. | $112.56 | 2024 | Fanapt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $108.80 | 2019 | |
| Braeburn INC. | $104.15 | 2024 | Brixadi |
| Esperion Therapeutics, INC. | $101.12 | 2020 | |
| Merck Sharp & Dohme LLC | $89.58 | 2020 | |
| Medtronic Vascular, INC. | $87.19 | 2019 | |
| Smith+Nephew, INC. | $42.88 | 2024 | Collagenase Santyl, Regranex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Gorbachev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.